(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 02 March 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III selexipag (Uptravi®) study will be shared during an oral presentation at the American College of Cardiology (ACC) Congress in San Diego, US. The abstract is now available on-line at the following link: The oral presentation, entitled 'Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study' will be given by Professor Vallerie McLaughlin of the University of Michigan Health System Division of Cardiovascular Medicine in Ann Arbor, Michigan, US at 12:00pm on March 15th. The data presentation...
↧